Core Viewpoint - The company experienced a reduction in losses for 2025, but revenue and gross margin were under pressure due to price reductions from core products in centralized procurement [1][2]. Financial Performance - In 2025, the company achieved operating revenue of 433 million yuan, a year-on-year decrease of 16.12% - The net profit attributable to shareholders was -55.85 million yuan, representing a year-on-year reduction in losses of 24.94% - The performance changes were primarily influenced by price reductions of core centralized procurement products (Dengzhanxixin capsules and Dengzhanxixin injections) and a decline in gross margin, although the company managed to lower expenses through optimized sales strategies [2]. Recent Events - On December 22, 2025, the company announced that the former actual controller, Lin Yan, was sentenced to three years in prison and fined for breaching trust and harming the interests of the listed company, with related illegal gains being recovered - Despite the conclusion of this legal matter, the long-term impact on the company's governance structure remains a concern for the market [3]. Industry Policy and Environment - The biopharmaceutical industry continues to face pressures from policy adjustments in medical insurance directories and price reductions from centralized procurement - In 2025, the National Medical Insurance Administration added a directory for innovative drugs under commercial insurance, providing new pathways for payment of innovative drugs, but competition intensifies challenges for traditional Chinese medicine companies - The company must continuously address profitability pressures arising from price declines [4]. Capital Movements - In December 2025, the high-tech Jia partnership among the top ten shareholders completed a full exit after five years, potentially leading to a loss - Changes in major shareholders may affect the stability of the company's equity structure, necessitating attention to future changes in shareholder composition [5].

Core Viewpoint - The company reported a revenue decline of 16.12% in 2025, with a net profit loss of 55.84 million yuan, although it reduced its loss by 24.94% compared to the previous year [1] Financial Performance - In 2025, the company achieved a revenue of 433 million yuan, down from the previous year [1] - The net profit attributable to shareholders was -55.84 million yuan, indicating a reduction in losses compared to the previous year [1] - The company has experienced consecutive losses for four years, with net profits of -48.91 million yuan in 2022, -12.20 million yuan in 2023, -74.40 million yuan in 2024, and -55.84 million yuan in 2025 [2] Legal Issues - The former actual controller of the company was sentenced for damaging the company's interests, involving illegal financial activities that misappropriated company funds for personal use [3][4] - The court sentenced the former chairman to three years in prison and imposed a fine of 5 million yuan, while the former financial director received a sentence of one year and six months with a fine of 200,000 yuan [4] - The company received 62 million yuan in execution funds from the court as a result of the legal proceedings [5] Market Performance - As of the close on February 12, the company's stock price fell by 1.92%, trading at 9.18 yuan per share, with a total market capitalization of 1.138 billion yuan [6]

Core Viewpoint - Lin Yanhe, the former chairman of Bio Valley, was sentenced to three years in prison for illegally transferring company funds to Shenzhen Jinsha River Investment Co., Ltd. The court rejected his request for probation [1][2]. Group 1: Legal Proceedings - Lin Yanhe was convicted of breaching trust and harming the interests of the listed company, receiving a three-year prison sentence and a fine of 5 million RMB. The former board secretary and financial director, He Yuan, was sentenced to 18 months in prison and fined 2 million RMB [2]. - The court ruled that the amount involved was particularly large and the social harm was severe, leading to the rejection of the defendants' requests for leniency based on self-reporting and contributions to damage control [2]. Group 2: Company Background - Bio Valley specializes in traditional Chinese medicine products, with its main products including Dan Zhan Sheng Mai capsules and Dan Zhan Xi Xin injections, which are used to treat ischemic cardiovascular and cerebrovascular diseases [2]. - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. Group 3: Financial Misconduct Details - From August 2021 to March 2022, Lin Yanhe arranged for He Yuan to transfer a total of 277 million RMB in non-operating funds to Jinsha River Investment under the guise of entrusted financial management, with 122 million RMB in 2021 and 155 million RMB in early 2022 [4]. - As of July 19, 2022, only 20 million RMB of the occupied funds had been returned, leaving 257 million RMB outstanding [4]. Group 4: Regulatory Actions - Lin Yanhe faced investigation by the China Securities Regulatory Commission (CSRC) in May 2022 for information disclosure violations and was publicly reprimanded by the Beijing Stock Exchange in July 2022 for fund occupation [3]. - He resigned as chairman in July 2022 and was banned from the securities market for life in September 2022 [3].

Core Viewpoint - The company, Zhejiang Shapuaisi Pharmaceutical Co., Ltd., has responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, particularly focusing on its investment in Shanghai Xinhong Pharmaceutical Co., Ltd. and the acquisition of shares in Yunnan Biological Valley Pharmaceutical Co., Ltd. [1][2] Investment in Shanghai Xinhong - The company, along with partners, invested a total of 460 million yuan in Shanghai Xinhong, with the company contributing 160 million yuan for a 34.7% stake [1][2] - The investment aims to leverage synergies between the company and Yunnan Biological Valley, which specializes in traditional Chinese medicine, particularly in cardiovascular disease treatments [2][4] Financial Performance of Yunnan Biological Valley - Yunnan Biological Valley reported revenues of 587 million yuan, 622 million yuan, and 516 million yuan over the last three years, with net losses of 49 million yuan, 12 million yuan, and 74 million yuan respectively [1][2] - The company recognized an investment loss of 7.22 million yuan related to its stake in Shanghai Xinhong due to Yunnan Biological Valley's losses in 2024 [1][2] Market Context - The increasing prevalence of cardiovascular diseases in China, with 330 million patients reported, highlights a growing market for related pharmaceuticals, particularly traditional Chinese medicine [4][3] - The company anticipates significant growth in the market for cardiovascular traditional Chinese medicine products, driven by an aging population and rising health awareness [4][3] Internal Decision-Making and Compliance - The company asserts that its investment decisions followed internal procedures compliant with the Company Law and relevant regulations, and the investment amount did not exceed 10% of its audited net assets [11][12] - Independent directors have confirmed that the investment process was conducted properly and did not harm the interests of the company or its minority shareholders [11][12] Other Investments - As of the end of 2024, the company reported long-term equity investments totaling 307 million yuan and other non-current financial assets of 20.4 million yuan, with additional investments in various pharmaceutical companies [12][15] - The company has engaged in risk investments, purchasing stocks worth 1.079 billion yuan and selling stocks worth 940 million yuan, resulting in a loss of 25 million yuan [12][15]